# A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET

Source: https://onco.cc/trials/nct05050942/  
OnCo record `nct05050942` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of CAM2029 (octreotide subcutaneous depot) run by Camurus AB, active.

## Summary

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET is a phase 3 interventional study registered as NCT05050942 by Camurus AB, with 332 participants enrolled, started 2021-10-22. Conditions listed: Gastro-enteropancreatic Neuroendocrine Tumor. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05050942
- Phase: 3
- Setting: A Randomized, Multi-center, Open-label, Active-controlled Phase 3 Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) Versus Octreotide LAR or Lanreotide ATG in Patients With GEP-NET
- Sponsor: Camurus AB
- Enrolled: 332

## Sources

- ClinicalTrials.gov NCT05050942: https://clinicaltrials.gov/study/NCT05050942

## Connected records

- drugs: [CAM2029 (octreotide subcutaneous depot)](https://onco.cc/drugs/cam2029/)

---
JSON: https://onco.cc/api/v1/entities/nct05050942.json